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Background: Device-associated healthcare-acquired infections (DA-HAI) pose a threat to patient safety, particularly
in the intensive care unit (ICU). We report the results of the International Infection Control Consortium (INICC) study
conducted in Turkey from August 2003 through October 2012.
Methods: A DA-HAI surveillance study in 63 adult, paediatric ICUs and neonatal ICUs (NICUs) from 29 hospitals, in
19 cities using the methods and definitions of the U.S. NHSN and INICC methods.
Results: We collected prospective data from 94,498 ICU patients for 647,316 bed days. Pooled DA-HAI rates for
adult and paediatric ICUs were 11.1 central line-associated bloodstream infections (CLABSIs) per 1000 central line
(CL)-days, 21.4 ventilator-associated pneumonias (VAPs) per 1000 mechanical ventilator (MV)-days and 7.5
catheter-associated urinary tract infections (CAUTIs) per 1000 urinary catheter-days. Pooled DA-HAI rates for NICUs
were 30 CLABSIs per 1000 CL-days, and 15.8 VAPs per 1000 MV-days. Extra length of stay (LOS) in adult and
paediatric ICUs was 19.4 for CLABSI, 8.7 for VAP and 10.1 for CAUTI. Extra LOS in NICUs was 13.1 for patients with
CLABSI and 16.2 for patients with VAP. Extra crude mortality was 12% for CLABSI, 19.4% for VAP and 10.5% for CAUTI
in ICUs, and 15.4% for CLABSI and 10.5% for VAP in NICUs. Pooled device use (DU) ratios for adult and paediatric
ICUs were 0.54 for MV, 0.65 for CL and 0.88 for UC, and 0.12 for MV, and 0.09 for CL in NICUs. The CLABSI rate was
8.5 per 1,000 CL days in the Medical Surgical ICUs included in this study, which is higher than the INICC report rate
of 4.9, and more than eight times higher than the NHSN rate of 0.9. Similarly, the VAP and CAUTI rates were higher
compared with U.S. NHSN (22.3 vs. 1.1 for VAP; 7.9 vs. 1.2 for CAUTI) and with the INICC report (22.3 vs. 16.5 in VAP;
7.9 vs. 5.3 in CAUTI).
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Conclusions: DA-HAI rates and DU ratios in our ICUs were higher than those reported in the INICC global report
and in the US NHSN report.
Keywords: Hospital infection, Nosocomial infection, Healthcare-associated infection, INICC, International Nosocomial
Infection Consortium, Turkey, Device-associated infection, Antibiotic resistance, Ventilator-associated pneumonia,
Catheter-associated urinary tract infection, Central line-associated bloodstream infections, Bloodstream infection,
Urinary tract infection, NetworkBackground
Increasingly in scientific literature, DA-HAIs are consid-
ered to be among the principal threat to patient safety in
the ICU and are among the main causes of patient mor-
bidity and mortality [1,2].
The effectiveness of implementing an integrated infec-
tion control programme focused on device-associated
healthcare-acquired infection (DA-HAI) surveillance
was demonstrated in the many studies conducted in the
U.S., whose results reported not only that the incidence
of DA-HAI can be reduced by as much as 30%, but that
a related reduction in healthcare costs was also feasible
[3]. In the same way, it is fundamental to address the
burden of antimicrobial-resistant infections that the
pathogens and the susceptibility to antimicrobials of
DA-HAI-associated pathogens be reported, so that in-
formed decisions can be made to effectively prevent
transmission of resistant strains and their determinants,
such as strains with phenotypes with very few available
treatments with chances of success [4].
For more than 30 years, the U.S. the Centers for Disease
Control and Prevention (CDC)’s National Healthcare Safety
Network (NHSN) [5] has provided benchmarking U.S. ICU
data on DA-HAIs, which have proven invaluable for re-
searchers [5], and served as an inspiration to the INICC [6].
The INICC is an international non-profit, open, multi-Table 1 Characteristics of the participating intensive care uni
<200 beds hospitals 201-500 bed hospitals
No. of hospitals 3 (10%) 8 (28%)
No. of ICUs 4 (6%) 20 (32%)
Medical Cardiac 1 (25%) 2 (50%)
Cardiothoracic 0 (0%) 1 (33%)
Medical 0 (0%) 4 (44%)
Medical/Surgical 1 (5%) 5 (26%)
Neonatal 1 (17%) 2 (33%)
Neurologic 0 (0%) 0 (0%)
Neurosurgical 0 (0%) 1 (33%)
Paediatric 1 (14%) 1 (14%)
Respiratory 0 (0%) 1 (50%)
Surgical 0 (0%) 3 (38%)
ICU, intensive care unit.centre, collaborative healthcare-associated infection control
programme with a surveillance system based on that of the
CDC’s NHSN [5]. Founded in Argentina in 1998, INICC is
the first multinational research network established to
measure, control and reduce DA-HAI in ICUs and surgical
site infections (SSIs) hospital wide through the analysis of
data collected on a voluntary basis by a pool of hospitals
worldwide [6,7]. The INICC has the following goals: To
create a dynamic global network of hospitals worldwide
and conduct surveillance of DA-HAIs and SSIs using
standardized definitions and established methodologies, to
promote the implementation of evidence-based infection
control practices, and to carry out applied infection control
research; to provide training and surveillance tools to indi-
vidual hospitals which can allow them to conduct outcome
and process surveillance of DA-HAIs and SSIs, to measure
their consequences, and assess the impact of infection
control practices; to improve the safety and quality of
healthcare world-wide through the implementation of sys-
tematized programmes to reduce rates of DA-HAIs and
SSIs, their associated mortality, excess lengths of stay
(LOS), excess costs, antibiotic usage, and bacterial resist-
ance [8].
This report is a summary of data on DA-HAIs col-
lected in 63 intensive care units (ICUs) in 29 Turkish
hospitals from 19 cities participating in the Internationalts
501-1000 bed hospitals >1000 bed hospitals Overall
10 (34%) 8 (28%) 29 (100%)
29 (46%) 10 (16%) 63 (100%)
1 (25%) 0 (0%) 4 (100%)
1 (33%) 1 (33%) 3 (100%)
3 (33%) 2 (22%) 9 (100%)
9 (47%) 4 (21%) 19 (100%)
2 (33%) 1 (17%) 6 (100%)
2 (100%) 0 (0%) 2 (100%)
2 (67%) 0 (0%) 3 (100%)
4 (57%) 1 (14%) 7 (100%)
1 (50%) 0 (0%) 2 (100%)
4 (50%) 1 (13%) 8 (100%)
Table 2 Pooled means of central line-associated bloodstream infection rates, urinary catheter-associated urinary tract infection rates, and ventilator-associated
pneumonia by hospital size
Hospital size,
beds, n
ICUs, n Patients, n Bed days, n CL days, n CLABSI, n CLABSI rate
(95% CI)
MV days, n VAP, n VAP, Rate (95% CI) UC days, n CAUTI, n CAUTI, rate
(95% CI)
<200 3 713 14 706 9,459 41 4.3 (31 – 5.9) 7,536 40 5.3 (3.8 - 7.2) 10 621 43 4.0 (2.9 - 5.5)
201-500 18 23 896 167 058 88 917 382 4.3 (3.9 – 4.7) 84 714 2193 25.9 (24.8 - 26.9) 142 965 652 4.6 (4.2 - 4.9)
501-1000 27 61 350 382 283 189 728 1,939 10.2 (9.8 – 10.7) 142 735 3152 22.1 (21.3 - 22.8) 314 847 2957 9.4 (9.0 - 9.7)
>1000 9 5,109 4,914 31 432 329 10.5 (9.4 – 11.7) 37 310 431 11.6 (10.4 - 12.7) 42 106 180 4.3 (3.7 - 4.9)
Pooled 57 91 068 613,191 319 536 2,691 8.4 (8.1 – 8.7) 272 295 5,816 21.4 (20.8 - 21.9) 510 539 3,832 7.5 (7.3 - 7.7)
Adult and Paediatric Patients. DA module, 2003-2012
ICU, intensive care units; CL, central line; CLABSI, central line-associated bloodstream infection; CI, confidence interval; MV, mechanical ventilator; VAP, ventilator-associated pneumonia; UC, urinary catheter; CAUTI,



























ICUs, n Patients, n Bed days, n CL days CLABSI, N CLABSI rate (95% CI) MV days, n VAP, n VAP, rate (95% CI)
<200 1 440 4,457 269 29 107.8 (72.2 – 154.8) 273 11 40.3 (20.2 - 70.9)
201-500 2 383 4,834 1706 6 3.5 (1.3 – 7.7) 1,206 19 15.8 (9.0 - 24.5)
501-1000 2 1,442 16 826 2206 51 23.1 (17.2 – 30.4) 3,046 28 9.2 (6.1 - 13.2)
>1000 1 1,165 8,008 1049 24 22.9 (14.7 – 34.0) 985 29 29.4 (19.8 - 42.0)
Pooled 6 3,430 34 125 5,230 110 21.0 (17.3 – 25.3) 5,510 87 15.8 (12.6 - 19.5)
Neonatal Patients. DA module, 2003–2012.
ICU, intensive care units; CL, central line; CLABSI, central line-associated bloodstream infection; CI, confidence interval; MV, mechanical ventilator; VAP,
ventilator-associated pneumonia.
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tween August 2003 and October 2012 [6,7].
Methods
Setting and study design
This prospective cohort surveillance study was con-
ducted in 63 adult, paediatric ICUs and neonatal ICUs
(NICUs) from 29 hospitals in 19 cities. Hospitals were
stratified by bed numbers (<200, 201–500, 501–1000,
and >1000).
The ICUs were stratified according to the patient features:
adult, paediatric or NICUs. The types of ICU participating
in this study were the following: Cardiothoracic, Medical,
Medical Cardiac, Medical/Surgical, Neurologic, Neurosurgi-
cal, Neonatal, Paediatric, Respiratory and Surgical.
According to the level of complexity of care, the
NICUs included the following levels:
 Level IIIA: It provides care to neonatal patients born
at ≥28 weeks, who weigh ≥1,000 grams. The provide
mechanical ventilation and minor surgical
procedures, such as umbilical vessel catheterization.Table 4 Pooled means and key percentiles of the distribution
type of location, adult and paediatric patients
Type of ICU ICU, n Patients Bed
days
CL days CLAB
Medical Cardiac 4 5,380 22 743 10 838 46
Cardiothoracic 3 7,800 21 796 15 165 22
Medical 9 21 854 170 042 79 343 525
Medical/Surgical 19 19 410 175 470 113 597 969
Neurologic 2 3,784 30 966 8,690 91
Neurosurgical 3 5,691 39 719 18 579 103
Paediatric 7 4,235 32 148 12 880 122
Respiratory 2 1,754 14 054 4,950 59
Surgical 8 21 160 106 253 55 494 754
Pooled 57 91 068 613 191 319 536 2,691
DA module, 2003–2012.
ICU, intensive care unit; CL, central line; CLABSI, central line-associated bloodstream
*Comparisons of the percentile distribution were made if there were at least 7 loca Level IIIB: It provides care to neonatal patients born
at any viable gestational age. Mechanical ventilation
and high-frequency mechanical ventilation are pro-
vided. There are paediatric surgical centres on site
or nearby to complete major surgical procedures.
 Level IIIC: It provides the highest level of NICU care.
In addition to the capabilities of Level IIIA and B, it
provides extra corporeal membrane oxygenation and
complicated surgical procedures requiring
cardiopulmonary bypass are performed as well.
INICC methodology
The INICC is focused on the surveillance and preven-
tion of DA-HAI in adult, paediatric ICUs and neonatal
ICUs (NICUs), and of SSIs in surgical procedures
hospital wide [6,7]. The INICC has both outcome sur-
veillance and process surveillance components. The
modules of the components may be used singly or sim-
ultaneously, but, once selected; they must be used for a
minimum of 1 calendar month. All DA-HAIs and SSIs
of the Outcome Surveillance Component are categorized




10 25 50 75 90
4.2 3.1 – 5.7 - - - - -
1.5 0.9 – 2.2 - - - - -
6.6 6.1 – 7.2 2.5 3.8 7.3 11.1 -
8.5 8.0 – 9.1 0.0 4.2 11.7 15.1 18.3
10.5 8.4 – 12.9 - - - - -
5.5 4.5 – 6.7 - - - - -
9.5 7.9 – 11.3 0.0 2.7 10.6 13.6 -
11.9 9.1 – 15.4 - - - - -
13.6 12.6 – 14.6 1.6 3.5 9.8 17.2 -
8.4 8.1 – 8.7 1.0 3.9 8.6 13.8 18.2
infection; CI, confidence interval.
tions contributing to the strata.
Table 5 Pooled means of the distribution of central line-associated bloodstream infection rates for level III NICUs,
stratified by birth-weight category
Birth-weight category ICU, n Patients Bed days CL days CLABSI, n CLABSI rate 95% CI
<750 grams 4 98 617 250 9 36.0 16.5 – 68.3
751-1000 grams 6 297 4,197 1,639 30 18.3 12.3 – 26.1
1001-1500 grams 6 649 10 652 1,465 48 32.8 24.2 – 43.4
1501-2500 grams 6 1,202 10 998 1,024 8 7.8 3.4 – 15.4
>2500 grams 6 1,184 7,661 852 15 17.6 9.9 – 29.0
Pooled 6 3,430 34 125 5,230 110 21.0 17.3 – 25.3
DA module, 2003–2012.
ICU, intensive care unit; CL, central line; CLABSI, central line-associated bloodstream infection; CI, confidence interval.
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confirmed BSIs are recorded and reported [9].
The Outcome Surveillance Component related to DA-
HAI classifies surveillance data into specific module proto-
cols that include excess LOS, evaluation of DA-HAI costs,
crude excess length of stay, crude excess mortality, micro-
biological profile, bacterial resistance, and antimicrobial-use
data. Data on DA-HAI costs were not included in this re-
port. Data from the INICC Process Surveillance Module,
which includes monitoring of hand hygiene, vascular cath-
eter care, urinary catheter care, and mechanical ventilator
care compliance, were not included in this report.
Training, validation, and reporting
The INICC Chairman trained the principal and second-
ary investigators at hospitals. Investigators were also
provided with a manual and training tool that described
in detail how to perform surveillance and complete sur-
veillance forms. In addition, investigators had continu-
ous e-mail and telephone access to a support team at
the INICC Central Office in Buenos Aires, Argentina.Table 6 Pooled means and key percentiles of the distribution
location, adult and paediatric patients





Medical Cardiac 4 5, 380 22 743 5,820 58
Cardiothoracic 3 7,800 21 796 9,993 123
Medical 9 21 854 170 042 82 378 1836
Medical/Surgical 19 19 410 175 470 95 021 2116
Neurologic 2 3,784 30 966 7,405 176
Neurosurgical 3 5,691 39 719 8,859 252
Paediatric 7 4,235 32 148 17 068 200
Respiratory 2 1,754 14 054 8,156 204
Surgical 8 21 160 106 253 37 595 851
Pooled 57 91 068 613 191 272 295 5,81
DA module, 2003–2012.
ICU, intensive care unit; MV, mechanical ventilator; VAP, ventilator-associated pneum
*Comparisons of the percentile distribution were made if there were at least 7 locaEach month, participating hospitals submitted the
completed surveillance forms to the INICC Central Of-
fice, where the validity of each case was checked and the
recorded signs and symptoms of infection and the re-
sults of laboratory studies, radiographic studies, and cul-
tures were scrutinized to assure that the U.S. NHSN
criteria for DA-HAI had been met. The forms used for
surveillance of each ICU patient permit both internal
and external validation, because they include every clin-
ical and microbiological criterion for each type of DA-
HAI [6,8]. Therefore, the investigator who reviewed the
data forms filled in at the participating hospital verified
that adequate criteria for infection had been fulfilled in
each case; and the original patient data form was further
validated at the INICC Central Office before data on the
reported infection are entered into the INICC’s database.
Data collection
Using standardized INICC detailed forms and following
the INICC protocol and U.S. NHSN’s definitions [9], in-




10 25 50 75 90
10.0 7.6 –12.9 - - - - -
12.3 10.2 – 14.7 - - - - -
22.3 21.3 – 23.3 8.3 12.6 22.1 32.7 -
22.3 21.3 – 23.2 9.6 12.8 16.5 28.6 42.9
23.8 20.4 – 27.6 - - - - -
28.4 25.0 – 32.2 - - - - -
11.7 10.2 – 13.5 2.9 6.2 10.6 14.1 -
25.0 21.7 – 28.7 - - - - -
22.6 21.1 – 24.2 12.6 18.5 21.9 26.7 -
6 21.4 20.8 – 21.9 7.2 11.2 20.5 27.7 35.4
onia; CI, confidence interval.
tions contributing to the strata.
Table 7 Pooled means of the distribution of ventilator-associated pneumonia rates for level III NICUs, stratified by
Birth-weight category
Birth-weight category ICUs, n Patients Bed days MV days VAP, n VAP rate 95% CI
<750 grams 4 98 617 236 4 16.9 4.6 – 43.4
751-1000 grams 6 297 4197 1,407 25 17.8 11.5 – 26.2
1001-1500 grams 6 649 10 652 1,307 19 14.5 8.8 – 22.7
1501-2500 grams 6 1,202 10 998 1,318 19 14.4 8.7 – 22.5
>2500 grams 6 1,184 7,661 1,242 20 16.1 9.8 – 24.9
Pooled 6 3,430 34 125 5,510 87 15.8 12.6 – 19.5
DA module, 2003-2012.
ICU, intensive care unit; MV, mechanical ventilator; VAP, ventilator-associated pneumonia; CI, confidence interval.
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HAIs, collected data on central line-associated blood-
stream infections (CLABSIs), catheter-associated urinary
tract infections (CAUTIs) and ventilator-associated
pneumonias (VAPs) in the ICUs.
In the NICUs, ICPs collected data on CLABSIs and um-
bilical catheter-associated primary bloodstream infections
or VAPs for each of 5 birth-weight categories (<750 g,
750–1000 g, 1001 – 1500 g, 1501 – 2500 g, >2500 g), Cor-
responding denominator data, patient-days and specific
device-days were also collected by the ICPs.
Detailed and aggregated data were used to calculate
DA-HAI rates per 1000 device-days. Only prospective
data using INICC patient detailed forms were used to
calculate mortality and LOS.
In accordance with the INICC’s Charter, the identity
of all INICC hospitals and cities is kept confidential.
Data analysis
Data for adult combined medical/surgical ICUs were not
stratified by type or size of hospital. Data for NICUs wereTable 8 Pooled means and key percentiles of the distribution
rates, by type of location, adult and paediatric patients





Medical Cardiac 4 5,380 22 743 14 907 49
Cardiothoracic 3 7,800 21 796 18 744 68
Medical 9 21 854 170 042 143 455 739
Medical/Surgical 19 19 410 175 470 154 422 1,22
Neurologic 2 3,784 30 966 29 856 596
Neurosurgical 3 5,691 39 719 36 688 347
Paediatric 7 4,235 32 148 10 981 73
Respiratory 2 1,754 14 054 12 833 50
Surgical 8 21 160 106 253 88 653 690
Pooled 57 91 068 613 191 510 539 3,83
DA module, 2003–2012.
ICU, intensive care unit; UC, urinary catheter; CAUTI, catheter-associated urinary trac
*Comparisons of the percentile distribution were made if there were at least 7 locastratified by weight categories: central line-days, urinary
catheter-days, or ventilator days.
Device-days consisted of the total number of central
line (CL)-days, urinary catheter (UC)-days, or mechan-
ical ventilator (MV)-days. For NICUs, device-days con-
sisted of the total number of CL-days, UC-days, and
MV-days.
Crude excess mortality of DA-HAI equals crude mor-
tality of ICU patients with DA-HAI minus crude mortal-
ity of patients without DA-HAI.
Crude excess LOS of DA-HAI equals crude LOS of
ICU patients with DA-HAI minus crude LOS of patients
without DA-HAI.
Comparisons of the percentile distribution were made
if there were at least 7 locations contributing to the
strata.
EpiInfo® version 6.04b (CDC, Atlanta, GA) and SPSS
16.0 (SPSS Inc. an IBM company, Chicago, Illinois) were
used to conduct data analysis. Relative risk (RR) ratios,
95% confidence intervals (CIs) and P-values were deter-




10 25 50 75 90
3.3 2.4 - 4.3 - - - - -
3.6 2.8 - 4.6 - - - - -
5.2 4.8 - 5.5 2.1 2.8 4.0 8.9 -
0 7.9 7.5 - 8.4 2.1 2.8 5.8 9.1 13.7
20.0 18.4 - 21.6 - - - - -
9.5 8.5 - 10.5 - - - - -
6.6 5.2 - 8.4 1.1 1.8 3.9 10.7 -
3.9 2.9 - 5.1 - - - - -
7.8 7.2 - 8.4 1.7 2.8 5.5 8.9 -
2 7.5 7.3 - 7.7 1.7 2.6 4.9 8.5 14.2
t infection; CI, confidence interval.
tions contributing to the strata.
Table 9 Pooled means of the distribution of central line utilization ratios, urinary catheter utilization ratios, and
ventilator utilization ratios, by type of location, adult and paediatric patients
ICU type ICU, n Bed days CL days DUR, central line (95% CI) MV days DUR, MV (95% CI) UC days DUR, UC (95% CI)
Medical Cardiac 4 22 743 10 838 0.48 (0.47 – 0.48) 5,820 0.26 (0.25 – 0.26) 14 907 0.66 (0.65 – 0.66)
Cardiothoracic 3 21 796 15 165 0.70 (0.69 – 0.70) 9,993 0.46 (0.45 – 0.47) 18 744 0.86 (0.86 – 0.86)
Medical 9 170 042 79 343 0.47 (0.46 – 0.47) 82 378 0.48 (0.48 – 0.49) 143 455 0.84 (0.84 – 0.85)
Medical/Surgical 19 175 470 113 597 0.65 (0.65 – 0.65) 95 021 0.54 (0.54 – 0.54) 154 422 0.88 (0.88 – 0.88)
Neurologic 2 30 966 8,690 0.28 (0.28 – 0.29) 7,405 0.24 (0.23 – 0.24) 29 856 0.96 (0.96 – 0.97)
Neurosurgical 3 39 719 18 579 0.47 (0.46 – 0.47) 8,859 0.22 (0.22 – 0.23) 36 688 0.92 (0.92 – 0.93)
Paediatric 7 32 148 12 880 0.40 (0.40 – 0.41) 17 068 0.53 (0.53 – 0.54) 10 981 0.34 (0.34 – 0.35)
Respiratory 2 14 054 4,950 0.35 (0.34 – 0.36) 8,156 0.58 (0.57 – 0.59) 12 833 0.91 (0.91 – 0.92)
Surgical 8 106 253 55 494 0.52 (0.52 – 0.53) 37 595 0.35 (0.35 – 0.36) 88 653 0.83 (0.83 – 0.84)
Pooled 57 613 191 319 536 0.52 (0.52 – 0.52) 272 295 0.44 (0.44 – 0.45) 510 539 0.83 (0.83 – 0.83)
DA module, 2003–2012.
ICU, intensive care unit; CL, central line; MV, mechanical ventilator; UC, urinary catheter; DUR, device use ratio; CI, confidence interval.
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The characteristics of 63 ICUs from 29 hospitals in 19
cities from Turkey currently participating in INICC that
contributed data for this report are shown in Table 1.
The length of hospital’s participation in the INICC
Programme is as follows: mean length of participation ±
SD, 28.7 ± 25.7 months, range 3 to 85 months.
For the Outcome Surveillance Component, DA-HAI
rates, device utilization (DU) ratios, crude excess mortal-
ity by specific type of DA-HAI, microorganism profile
and bacterial resistance from August 2003 through
October 2012 are summarized (Tables 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12 and 13).
Table 2 shows DA-HAI rates by infection type
(CLABSI, CAUTI, VAP) in adult and paediatric ICUs
stratified by hospital size and Table 3 shows the same in-
formation regarding NICUs. In adult and paediatric pa-
tients, we found higher rates of CLABSI in the largest
hospitals (>500 beds), however, VAP and CAUTI rates
were higher in middle-sized hospitals (201–1000 beds).
In NICU patients the rates of CLABSI and VAP were
higher in the smallest hospitals (<200 beds).Table 10 Pooled means of the distribution of central line util
location, for level III NICUs
Birth-weight category ICU, n Bed days CL days
<750 grams 4 617 250
751-1000 grams 6 4197 1639
1001-1500 grams 6 10652 1465
1501-2500 grams 6 10998 1024
>2500 grams 6 7661 852
<750 grams 6 34125 5230
DA module, 2003–2012.
ICU, intensive care unit; CL, central line, MV, mechanical ventilator; DUR, device useTables 4, 5, 6, 7 and 8 show DA-HAI rates in all the
participating ICUs, and in those cases that include
NICU patients (Tables 5 and 7), the information is di-
vided by weight category. We found that in adult and
paediatric patients the highest CLABSI rate was found
in the Surgical ICUs, the highest VAP rate in Neurosur-
gical ICU, and the highest CAUTI rate in Neurologic
ICUs. Regarding NICU patients, the highest CLABSI
rate was found in patients within the 1000–1500 grams
weight category, and the highest VAP rate was found in
patients in the 751–1000 grams weight category.
Tables 9 and 10 provide data on device use ratios
(DURs) for CL, UC and MV and their respective confi-
dence intervals. Central line DUR was higher in the car-
diothoracic ICUs, the mechanical ventilator DUR was
higher in respiratory ICUs, and the urinary catheter DUR
was higher in neurologic ICUs. In the NICU patients the
highest DUR for central line and mechanical ventilator
were found in <750 grams birth weight category.
Table 11 provides data on crude ICU mortality in pa-
tients hospitalized in each type of unit during the surveil-
lance period, with and without DA-HAI, and crude excessization ratios and ventilator utilization ratios, by type of
DUR, central line (95% CI) MV days DUR, MV (95% CI)
0.41 (0.37 – 0.45) 236 0.38 (0.34 – 0.42)
0.39 (0.38 – 0.41) 1407 0.34 (0.32 – 0.35)
0.14 (0.13 – 0.14) 1307 0.12 (0.12 – 0.13)
0.09 (0.09 – 0.10) 1318 0.12 (0.11 – 0.13)
0.11 (0.10 – 0.12) 1242 0.16 (0.15 – 0.17)
0.15 (0.15 – 0.16) 5510 0.16 (0.16 – 0.17)
ratio; CI, confidence interval.
Table 11 Pooled means of the distribution of crude mortality and crude excess mortality of adult and paediatric
intensive care unit patients with and without device-associated healthcare-acquired infection
Adult and paediatric ICUs combined No. of deaths No. of patients Pooled crude mortality, % (95% CI) RR (95% CI)
Crude mortality of patients without DA-HAI 1,616 6,408 25.2 (24.1- 26.3) 1.0
Crude mortality of patients with CLABSI 133 357 37.3 (32.2- 42.4) 1.5 (1.2 – 1.8)
Crude excess mortality of patients with CLABSI 133 357 12.0 (8.1- 16.1) -
Crude mortality of patients with CAUTI 55 154 35.7 (28.1- 43.8) 1.4 (1.1 – 1.9)
Crude excess mortality of patients with CAUTI 55 154 10.5 (4.0- 17.5) -
Crude mortality of patients with VAP 253 567 44.6 (40.4- 48.8) 1.8 (1.6 – 2.0)
Crude excess mortality of patients with VAP 253 567 19.4 (16.3- 22.5) -
Neonatal ICUs combined No. of deaths No. of patients Pooled crude mortality, % (95% CI)
Crude mortality of patients without DA-HAI 68 1,964 3.5 (2.7- 4.4) 1.0
Crude mortality of patients with CLABSI 10 53 18.9 (9.4- 32.7) 5.5 (2.8 – 10.6)
Crude excess mortality of patients with CLABSI 10 53 15.4 (6.7- 28.3) -
Crude mortality of patients with VAP 6 43 14.0 (5.3- 27.9) 4.0 (1.8 – 9.3)
Crude excess mortality of patients with VAP 6 43 10.5 (2.6- 23.5) -
ICU, intensive care units; CI, confidence interval; DA-HAI, device-associated healthcare-acquired infection; CLABSI, central line-associated bloodstream infection;
VAP, ventilator-associated pneumonia; CAUTI, catheter-associated urinary tract infection; RR, relative risk.
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http://www.ann-clinmicrob.com/content/13/1/51mortality of adult and paediatric patients with CLABSI,
CAUTI, and VAP, and infants in NICUs with CLABSI or
VAP. The DA-HAI associated with a higher mortality was
VAP in adult and paediatric patients and CLABSI in
NICU patients.
Table 12 provides data on crude LOS of patients hospital-
ized in each ICU during the surveillance period with and
without DA-HAI and crude excess LOS of adult and paedi-
atric patients with CLABSI, CAUTI, and VAP and infants
in NICUs with CLABSI or VAP. The DA-HAI associatedTable 12 Pooled means of the distribution of the length of st
patients with and without device-associated healthcare-acqu
Adult and paediatric ICUs combined LOS, total days No. of p
LOS of patients without DA-HAI 50 716 6,408
LOS of patients with CLABSI 6,920 357
Extra LOS of patients with CLABSI 6,920 357
LOS of patients with CAUTI 2,769 154
Extra LOS of patients with CAUTI 2,769 154
LOS of patients with VAP 9,426 567
Extra LOS of patients with VAP 9,426 567
Neonatal ICUs combined LOS, total days No. of p
LOS of patients without DA-HAI 17,547 1,964
LOS of patients with CLABSI 1,169 53
Extra LOS of patients with CLABSI 1,169 53
LOS of patients with VAP 1,081 43
Extra LOS of patients with VAP 1,081 43
LOS, length of stay; DA-HAI, device-associated healthcare-acquired infection; CLABS
pneumonia; CAUTI, catheter-associated urinary tract infection.with a longer LOS was CLABSI in adult and paediatric pa-
tients and VAP in NICU patients.
Table 13 provides data on bacterial resistance of patho-
gens isolated from patients with DA-HAI in adult and
paediatric ICUs and NICUs. We found a high resistance
of Staphylococci aureus and Coagulase-negative staphylo-
cocci to oxacilin in CLABSIs, VAP and CAUTIs.
Tables 14 and 15 compare the results of this report
from Turkey with the INICC international report for the
period 2007–2012 and with NHSN report of 2011 [5,10].ay and crude excess length of stay of intensive care unit
ired infection
atients Pooled average. LOS, days (95% CI) RR (95% CI)
7.9 (7.8-7.9)
19.4 (17.5-21.6) 2.4 (2.4 – 2.5)
11.5 (9.7-13.7)
18.0 (15.4-21.2) 2.3 (2.2 – 2.3)
10.1 (7.6-13.3)
16.6 (15.3-18.1) 2.1 (2.0 – 2.1)
8.7 (7.5-10.2)
atients Pooled average LOS, days
8.9 (8.5-9.3)
22.1 (16.9-29.5) 2.6 (2.3 – 2.6)
13.1 (16.9-9.5)
25.1 (18.7-35.7) 2.8 (2.6 – 3.0)
16.2 (18.7-35.7)
I, central line-associated bloodstream infection; VAP, ventilator-associated











Pathogen, antimicrobial (CLABSI) (CLABSI) (VAP) (VAP) (CAUTI) (CAUTI)
Staphylococcus aureus
Oxacilin 478 92.7% 482 83.2% 22 81.8%
Coagulase- negative staphylococci
Oxacilin 516 90.3% 69 81.2% 14 71.4%
Enterococcus faecalis
Vancomycin 80 5.0% 10 0.0% 36 0.0%
Pseudomonas aeruginosa
Ciprofloxacine 201 35.3% 719 40.6% 89 36.0%
Piperacillin or piperacillin-tazobactam 279 27.6% 1,009 33.8% 124 31.5%
Amikacin 185 18.9% 671 18.3% 81 16.0%
Imipenem or meropenem 251 37.1% 989 41.0% 122 33.6%
Klebsiella pneumoniae
Ceftriaxone or ceftazidime 140 55.7% 160 46.3% 28 50.0%
Imipenem or meropenem 189 6.3% 224 4.5% 73 1.4%
Acinetobacter baumanii
Imipenem or meropenem 469 56.1% 844 62.8% 73 57.5%
Escherichia Coli
Ceftriaxone or ceftazidime 67 55.2% 77 44.2% 78 51.3%
Imipenem or meropenem 68 4.4% 141 3.5% 132 2.3%
Ciprofloxacine 65 66.2% 110 50.0% 104 33.7%
CLABSI, central line-associated bloodstream infection; VAP, ventilator-associated pneumonia; CAUTI, catheter-associated urinary tract infection.
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than in INICC and NHSN data, as shown in Table 14.
DUR was higher in most cases as well, but the central
line DUR was lower in paediatric ICUs and NICUs com-
pared to NHSN. Table 15 compares the antimicrobial re-
sistance rates of this report from Turkey with the INICC
international report for the period 2007–2012 and with
NHSN report of 2010–2012. In most cases, we found
higher resistance rates than those found in the NHSN
report.
Discussion
Within the scientific literature addressing the burden of
DA-HAIs in Turkey’s ICUs, in a recent study it was shown
that the DA-HAI rates found in their setting were higher
than the rates reported by the U.S. NHSN and INICC
[11]. The CLABSI rate of our study was similar to the rate
found in another study conducted in Turkey showing 11.8
CLABSIs per 1000 CL days [11]. Likewise, our CAUTI
rate was similar to the findings of another study from
ICUs in Turkey, showing 8.3 CAUTIs per 1000 UC days
[12]. The VAP rate in our study was 21.4 per 1000 MV-
days in adult and paediatric ICUs. Similarly, in 2008,Erdem et al. found a rate of 22.6 VAPs per 1000 MV-days
[13], and Leblebicioglu et al. found a global VAP rate of
26.5 VAPs per 1000 MV-days in a multi-site study carried
out in 12 hospitals in 2007 [12].
In our Turkish ICUs, DA-HAI rates and pooled DU
ratios were higher than the Global INICC Report and U.
S. NHSN’s data [5,6]. Likewise, the antimicrobial resist-
ance rates found in our ICUs were higher than U.S.
NHSN [4] and INICC [6] report rates for Staphyloccocus
aureus as resistant to oxacillin, and for Escherichia Coli
as resistant for imipenem. The resistance of Escherichia
Coli to ciprofloxacin also higher than than U.S. NHSN
[4], but similar to INICC report. [6] On the other hand,
the resistance rates for Pseudomonas aeruginosa were
higher in this study than U.S. NHSN report [4], but
lower than the INICC reported resistance rates [6], as
resistant to ciprofloxacin, piperacillin-tazobactam, ami-
kacin and imipenem or meropenem; for Escherichia Coli
as resistant to ceftriaxone and ceftazidime; and for Kleb-
siella pneumonia as resistant to ceftriaxone or ceftazi-
dime. By contrast, the resistance rates for Klebsiella
pneumonia and Acinetobacter baumanii as resistant to
imipenem and meropenem, and Enterococcus faecalis as
Table 14 Benchmarking of device-associated healthcare-acquired infection rates in this report against the report of the
International Nosocomial Infection Control Consortium (2007–20012) and the report of the US National Healthcare
Safety Network Data (2011)
This report INICC report (2007–2012) [10] U.S. NHSN report (2011) [5]
Medical surgical ICU
CL, DUR 0.65 (0.65 – 0.65) 0.54 (0.54 – 0.54) 0.35 (0.35 – 0.35)
CLABSI rate 8.5 (8.0 – 9.1) 4.9 (4.8 – 5.1) 0.9 (0.8 - 0.9)
MV, DUR 0.54 (0.54 – 0.54) 0.36 (0.36 – 0.36) 0.24 (0.24 – 0.24)
VAP rate 22.3 (21.3 - 23.2) 16.5 (16.1 – 16.8) 1.1 (9.8 - 1.2)
UC, DUR 0.88 (0.88 – 0.88) 0.62 (0.62 – 0.62) 0.54 (0.54 – 0.54)
CAUTI rate 7.9 (7.5 - 8.4) 5.3 (5.2 – 5.8) 1.2 (1.1 - 1.3)
Paediatric ICU
CL, DUR 0.40 (0.40 – 0.41) 0.50 (0.50 – 0.50) 0.47 (0.46 – 0.47)
CLABSI rate 9.5 (7.9 – 11.3) 6.1 (5.7 – 6.5) 1.8 (1.6 - 1.9)
MV, DUR 0.53 (0.53 – 0.54) 0.53 (0.53 – 0.53) 0.40 (0.40 – 0.40)
VAP rate 11.7 (10.2 - 13.5) 7.9 (7.4 – 8.4) 1.1 (9.0 - 1.2)
UC, DUR 0.34 (0.34 – 0.35) 0.31 (0.31 – 0.32) 0.23 (0.22 – 0.23)
CAUTI rate 6.6 (5.2 - 8.4) 5.6 (5.1 – 6.1) 3.1 (2.7 - 3.5)
Neonatal ICU (weight 1501 to 2500 grams)
CL, DUR 0.09 (0.09 – 0.10) 0.21 (0.20 – 0.21) 0.18 (0.18 – 0.19)
CLABSI rate 7.8 (3.4 – 15.4) 4.8 (3.7 – 6.1) 0.7 (0.6 - 0.9)
MV, DUR 0.12 (0.11 – 0.13) 0.10 (0.10 – 0.11) 0.07 (0.07 – 0.07)
VAP rate 14.4 (8.7 - 22.5) 10.7 (8.4 – 13.4) 0.5 (0.2 - 0.9)
ICU, intensive care unit; CLABSI, central line-associated bloodstream infection; VAP, ventilator-associated pneumonia; CAUTI, catheter-associated urinary tract
infection; DUR, device use ratio; INICC, International Nosocomial Infection Control Consortium; U.S. NSHN, National Healthcare Safety Network of the United States
of America.
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http://www.ann-clinmicrob.com/content/13/1/51resistant to vancomycin, were lower in this study than in
INICC and U.S. NHSN reports [4,6].
These high DA-HAI rates may reflect the typical ICU
situation in hospitals in Turkey [14], and several reasons
have been exposed to explain this fact [11,15]. Among the
primary plausible causes, it can be mentioned that, in
Turkey there are still no legally enforceable rules or regula-
tions concerning the implementation of infection control
programs, such as national infection control guidelines; yet,
in the few cases in which there is a legal framework, adher-
ence to the bundles is most irregular and hospital accredit-
ation is not mandatory [16]. This situation is further
emphasized by the fact that administrative and financial
support is insufficient to fund infection control pro-
grammes, and invariably results in extremely low nurse-to-
patient staffing ratios—which have proved to be highly
connected to high DA-HAI rates in ICUs—, hospital over-
crowding, lack of medical supplies, out-dated medical sup-
plies and in an insufficient number of experienced nurses
or trained healthcare workers [14].
In order to reduce the hospitalized patients’ risk of in-
fection, DA-HAI surveillance is primary and essential, be-
cause it effectively describes and addresses the importance
and characteristics of the threatening situation created byDA-HAIs. This must be followed by the implementation
of practices aimed at DA-HAI prevention and control.
Additionally, participation in INICC has played a funda-
mental role, not only in increasing the awareness of DA-
HAI risks in the ICU, but also providing an exemplary
basis for the institution of infection control practices. Fi-
nally, it is of utmost importance to restrict the administra-
tion of anti-infective in order to effectively control of
antibiotic resistance.
The INICC programme is focused on surveillance of
DA-HAIs in the ICU and surveillance of SSIs hospital
wide; that is, healthcare settings (ICUs) and procedures
(Surgical Procedures) with the highest healthcare-acquired
rates, in which patients’ safety is most seriously threat-
ened, due to their critical condition and exposure to inva-
sive devices and surgical procedures [16]. Through the
last 12 years, INICC has undertaken a global effort in
America, Asia, Africa, Middle East, and Europe to
respond to the burden of DA-HAIs, and has achieved ex-
tremely successful results, by increasing HH compliance,
improving compliance with other infection control bun-
dles and interventions as described in several INICC pub-
lications, and consequently reducing the rates of DA-HAI
and mortality [6,17-21].
Table 15 Benchmarking of antimicrobial resistance rates in this report against the report of the International
Nosocomial Infection Control Consortium (2007–20012) and the report of the US National Healthcare Safety Network
Data (2009–2010)
This report resistance % INICC 2007–2012 resistance % NHSN 2009–2010 resistance, %
Pathogen, antimicrobial (CLABSI) (CLABSI) (CLABSI)
Staphylococcus aureus
Oxacillin 92.7% 61.2% 54.6%
Enterococcus faecalis
Vancomycin 5.0% 12.2% 9.5%
Pseudomonas aeruginosa
Ciprofloxacine 35.3% 37.5% 30.5%
Piperacillin or piperacillin-tazobactam 27.6% 33.5% 17.4%
Amikacin 18.9% 42.8% 10.0%
Imipenem or meropenem 37.1% 42.4% 26.1%
Klebsiella pneumoniae
Ceftriaxone or ceftazidime 55.7% 71.2% 28.8%
Imipenem or meropenem 6.3% 19.6% 12.8%
Acinetobacter baumanii
Imipenem or meropenem 56.1% 66.3% 62.6%
Escherichia Coli
Ceftriaxone or ceftazidime 55.2% 65.9% 19.0%
Imipenem or meropenem 4.4% 8.5% 1.9%
Ciprofloxacine 66.2% 69.3% 41.8%
CLABSI, central line-associated bloodstream infection.
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identified in this report, it is required that the hospital
concerned start by collecting their data by applying the
methods and methodology described for U.S. NHSN and
INICC, and then calculate infection rates and DU ratios
for the DA-HAI Module.
The particular and primary application of these data is
to serve as a guide for the implementation of prevention
strategies and other quality improvement efforts locally
for the reduction of DA-HAI rates to the minimum pos-
sible level.
Study limitations
The findings in this report are subject to at least two
limitations. First, we did not consider the difference in
time periods for the different data sources in the com-
parisons made with INICC and U.S. NHSN. Second, it is
unfortunate that the study did not include data on pos-
sible changes in DA-HAIs in Turkey throughout the
study period.
Conclusions
In conclusion, the data presented in this report fortify
the fact that DA-HAIs in Turkey pose a grave and many
times concealed risk to patient safety, as compared to
the developed world. It is INICC’s main goal to enhanceinfection control practices, by facilitating elemental,
feasible and inexpensive tools and resources to tackle
this problem effectively and systematically, leading to
greater and stricter adherence to infection control pro-
grams and guidelines, and to the correlated reduction in
DA-HAI and its adverse effects, in the hospitals partici-
pating in INICC, as well as at any other healthcare facil-
ity worldwide.
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